Comprehensive exploratory analyses of biomarkers were done in the phase III CheckMate 77T study of pre- and post-surgical treatment with the immunotherapy nivolumab in individuals with surgically resectable non-small-cell lung cancer. The analyses indicate that pre-surgical clearance of circulating tumour DNA, among other markers, is associated with improved clinical outcomes with nivolumab.